Allergan pays out $38 million over subsidiaries' sales practices

16 December 2016

Ireland-incorporated drugmaker Allergan (NYSE: AGN) has announced that a $38 million settlement fee has been agreed to bring to an end a US federal investigation over the sales and marketing practices of its Forest subsidiary companies.

The indirect subsidiaries, Forest Laboratories and Forest Pharmaceuticals, have reached a civil resolution with the government over its practices in relation to three products in a period from 2008 to 2011.

These products are the hypertension therapy Bystolic (nebivolol), the fibromyalgia medication Savella (milnacipran) and the Alzheimer's disease drug Namenda (memantine).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK